Eli Lilly stock fell sharply after the drug maker posted quarterly earnings that missed analysts’ expectations, and lowered its guidance. Lilly has risen to become one of the most valuable companies in the world with a market capitalization of $859 billion, much due to soaring demand for its GLP-1 weight loss and diabetes drugs Zepbound and Mounjaro. This quarter, however, sales of the blockbuster drugs came up well short of expectations.